Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals's GHG Emissions Data Preview
In 2024, Ionis Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, Ionis Pharmaceuticals has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Total Scope 2 | ||||
Market-Based | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Location-Based | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 1 Revenue Intensity (tCO2e/$M) | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Verified Sources Behind Ionis Pharmaceuticals’s Greenhouse Gas (GHG) Emissions Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Ionis Pharmaceuticals’s data sources below and access millions more through our Disclosure Search.
Insights into Ionis Pharmaceuticals's Operational Emissions
In 2024, the total operational greenhouse gas (GHG) emissions of Ionis Pharmaceuticals amounted to 5,146 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2). a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Ionis Pharmaceuticals decreased by 6.15%, showing that the company has made progress in taking action to reduce the climate impact of its operations. a
Ionis Pharmaceuticals's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Ionis Pharmaceuticals's Scope 1 emissions?
In 2024, the total Scope 1 emissions of Ionis Pharmaceuticals were 2,616 metric tons of CO₂ equivalent (tCO₂e). a
Has Ionis Pharmaceuticals reduced its Scope 1 emissions over time?
Since 2021, Ionis Pharmaceuticals's Scope 1 emissions have increased by 1.95%, reflecting a rising long-term trend in Scope 1 emissions over time. a b
Compared to the previous year (2023), Ionis Pharmaceuticals's Scope 1 emissions decreased by 2.93%, highlighting the company's efforts to lower direct emissions from assets it owns or controls. a
What are Ionis Pharmaceuticals's Scope 2 emissions?
In 2024, Ionis Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 2,530 tCO₂e using the market-based method. a
Has Ionis Pharmaceuticals reduced its Scope 2 emissions over time?
Since 2021, Ionis Pharmaceuticals's Scope 2 greenhouse gas (GHG) emissions ( Market-Based) have increased by 23.29%, reflecting a rising long-term trend in Scope 2 emissions over time. a b
Compared to the previous year (2023), Ionis Pharmaceuticals's Scope 2 emissions (Market-Based) have remained relatively stable, indicating that Ionis Pharmaceuticals 's emissions have plateaued with no significant change in its energy consumption footprint. a
What methodology does Ionis Pharmaceuticals use for Scope 2 reporting?
In 2024, Ionis Pharmaceuticals reported its Scope 2 emissions using the market-based method. a
Ionis Pharmaceuticals's Scope 2 Emissions Over Time
- Total Scope 2 Market-Based
Insights into Ionis Pharmaceuticals’s GHG Emissions Intensity Compared to Industry Peers
In 2024, Ionis Pharmaceuticals reported Scope 1 greenhouse gas (GHG) emissions of 2,616 tCO₂e and total revenues of USD 705 millions. This translates into an emissions intensity of 3.71 tCO₂e per millions USD. a
Ionis Pharmaceuticals's Scope 1 Emissions Intensity Compared to Peers
How does Ionis Pharmaceuticals's GHG emissions intensity compare to its peers?
In 2024, Ionis Pharmaceuticals reported a Scope 1 emissions intensity of 3.71 tCO₂e per millions USD. Compared to the peer group median of 1.68 , this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors. a
Where does Ionis Pharmaceuticals rank on GHG emissions intensity within its industry?
In 2024, Ionis Pharmaceuticals ranked 19 out of 22 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD). a
This places Ionis Pharmaceuticals among the least efficient performers, with one of the highest emissions intensities in its sector. a